Represents the first approval in North America for its Single-Injection Osteoarthritis Treatment BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 20, 2009-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in ...

This week, Anika Therapeutics finally got an approval it’s been fighting nearly five years to get when U.S. regulators said yes to its one-shot treatment for osteoarthritis of the knee. This week, ...

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that ...

Anika Therapeutics announced that it has received FDA marketing approval for Monovisc (sodium hyaluronate [NaHA] in phosphate buffered saline), a single injection viscosupplement used to treat pain ...

A single injection treatment for pain due to Osteoarthritis of the knee, Monovisc is the first FDA-approved single injection product with HA from a non-animal source. NASDAQ:ANIK halted in AH trade ...

Shares of Anika Therapeutics soared as much as 62 percent this morning after the Bedford, MA-based developer announced that its osteoarthritis therapy won marketing approval in Canada. Monovisc ...

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today announced ...

MONTREAL, May 16, 2024 /CNW/ - Pendopharm, a division of Pharmascience Canada ("Pendopharm"), is pleased to announce the renewal of its exclusive distribution agreement with Anika Therapeutics Inc ...